VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and ...

Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting

- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics - SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic...

TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics

SAN DIEGO , May 18 /PRNewswire/ -- TriLink BioTechnologies, Inc. today announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor(R) Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor(R) XT-8 Syst...

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and leukemia, today announces the signature of an ...

Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin

Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical...

Midwest Research Institute Launches Clinical Molecular Diagnostics Laboratory

Receives CLIA Certification and CAP Accreditation PALM BAY, Fla., April 17 /PRNewswire-USNewswire/ -- To address the growing need for molecular diagnostics, officials at the Florida Division of Midwest Research Institute (MRI) announced today that they have established a Clinical Molecular Di...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) were presented at the Keystone Symposia on Mol...

Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State

Test aiding diagnosis of mental retardation, birth defects, and autism spectrum and developmental disorders now approved for use on patients in New York MADISON, N.J., March 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic ...

Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies of the IntelligentMDx BK Viral Quantitative Assay are complete. Under the verification protocol the Limit of De...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company's molecular breast cancer assay to predict risk of disease recurrence in ind...

Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA

Fourth 'Moderate Complexity' Categorization Highlights GeneXpert(R) System Ease-of-Use SUNNYVALE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the U.S. Food & Drug Administration (FDA) categorized Cepheid's Xpert(TM) MRSA/SA Blood ...

CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect

VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...

National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities

DENVER, Sept. 10 /PRNewswire-USNewswire/ -- National Jewish Health and Roche Diagnostics Corporation have reached a strategic agreement to pursue opportunities in the growing field of molecular diagnostics. This partnership will combine National Jewish's expertise in clinical testing and care ...

Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network

BIRMINGHAM, Ala., Sept. 4 /PRNewswire/ -- Southern Research Institute today announced that the National Institutes of Health (NIH) has selected the organization to participate in the newly-funded Molecular Libraries Probe Production Center Network (MLPCN). The MLPCN -- a collaborative research...

First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate

Identifies deadly hospital pathogens A single, fast and accurate test identifies four Staph strains simultaneously HUNTSVILLE, Ala., Aug. 4 /PRNewswire/ -- Diatherix Laboratories, an independent clinical reference laboratory located in the Huds...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

SOMERSET, N.J., July 21 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that a paper published in Molecular Cancer Therapeutics (2008; 7(7):1871-9) reports that a combination of ONCONASE (ranpirnase) and the thiazolidinedione antidiabetic drug rosiglitazone show...

BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections

BD GeneOhm(TM) Cdiff Assay Submitted for FDA Clearance SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today the CE marking of the BD GeneOhm(TM) Cdiff molecular assay for the rapid diagnosis of patie...

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies

Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer PHILADELPHIA, TOKYO and WOBURN, Mass, J...

AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients

-Specific biomarkers for molecular tumor grade and endocrine benefit offer better prediction of individual patient outcome- SAN DIEGO, May 13 /PRNewswire/ -- AviaraDx, Inc. today announced the publication of an article describing the discovery, development and validation of a new mol...

Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS

STOCKHOLM, April 22 /PRNewswire/ -- - Summary: Using Protein Tomography(TM), Sidec Investigated in Collaboration With Genmab the Molecular Mode of Action of Humax- EGFr (Zalutumumab). In This Study Sidec Showed That EGFr is Flexible and That Zalutumumab Locks the EGFr Into a Very Compact Ina...

Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO ) announced today that the Company has begun a pivotal U.S. clinical trial of its investigational APTIMA(R) assay to detect human papillomavirus (HPV), which causes cervical cancer. "Starting this highly comp...

Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics

The Next Step Involves Combining the 350+ Targeted Drugs on the Market and in Clinical Development with Each Other to Block Key Pathways to Combat Drug Resistance, Enhance Anticancer Effects, and Expand the Markets for Targeted Drugs LAKE FOREST, Calif., Feb. 19 ...

QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues

Project to Utilize World-Class Software & Database Developed in West Michigan to Help Advance Disease Diagnosis and Treatment Options VENLO, Netherlands and GRAND RAPIDS, Mich., Feb. 14 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced the formation of a collaborativ...

Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway

Contracts Give Access to Diagnostic Application of Research Technologies FULLERTON, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC ) announced today that it has signed four agreements with National University of Ireland, Galway (NUI Galway) to direct assay research...

Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases

SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(R) Tissue of Origin Test is the focus of a study published in the January issue of The Journal of Molecular Diagnostics. Pathwork's genomics-ba...

Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH ), is presenting data today at the AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference is being held October 22-26, 2007 at the Moscone Conv...

Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award

Abbott Innovations Honored for Third Time in Five Years ABBOTT PARK, Ill., Oct. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) has received a 2007 Chicago Innovation Award for its m2000(TM) molecular diagnostic instrument (http://www.abbott.com/global/url/content/en_US/60.15:15/fea...

Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

- RDEA119: A Potent and Selective MEK inhibitor with Favorable In Vitro and In Vivo Anti-Tumor Properties - CARLSBAD, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Pink Sheets: ARDC), a company focused on the discovery and development of small-molecule ther...

BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery

First Molecular Test to Simultaneously Identify Staphylococcus Aureus and Methicillin-Resistant Staphylococcus Aureus from Nasal Specimens SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today that it has ...

Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting

PHILADELPHIA--(BUSINESS WIRE)--Mar 19, 2007 - Avid Radiopharmaceuticals, Inc. (Avid), a product-focused molecular imaging company, today announced the presentation of the first results from a clinical study of 18F-AV-1/ZK (AV-1), a novel radiopharmaceutical for positron emission tomography (PET) im...

DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy

EVRY, France, April 12, 2007 /PRNewswire/ -- DNA Therapeutics S.A. an emerging pharmaceutical company specialized in innovative cancer therapy announces today the elucidation of a new mechanism of action and the identification of a biomarker of its first-in-class antitumoral lead molecule Dbait. I...

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

The research, done in collaboration with the Centro de Investigación Médica Aplicada (CIMA) at the University of Navarra, Pamplona, Spain, is being presented at Porphyrins and Porphyrias Congress, Rotterdam, the Netherlands. AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam Mole...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at Molecular Insight Pharmaceuticals today announced the presentation of preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 54th...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ma and GAAP measures, which is explained later in this release. As a result of selling Isis' diagnostic subsidiary, Ibis Biosciences, to Abbott molecular Inc. (AMI) in the first quarter of 2009, Isis is reporting Ibis' financial results as discontinued operations. Accordingly, Isis has presented all pe...

DNA Helps Reunite Children With Their Families

...even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...y. With more than 2,600 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients nationwide. Rather than competing with its clients for physician office business, ARUP chooses instead to support cli...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

...arch project into prostate cancer, the Dutch CTMM (Center for Translational molecular Medicine) today announced the successful completion of 265 million euro fun...e Dutch government. About CTMM CTMM (Center for Translational molecular Medicine) is a Netherlands-based public-private partnership dedicated to th...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

... has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of...

Correction to Earlier Release From Jewish Hospital and University of Louisville

...ng the press conference Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for molecular Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference between what we have done and what another institu...

World's First Cardiac Adult Stem Cell Patient Receives Infusion

... Study leader Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for molecular Cardiology said, "We continue to enroll patients in this first-of-its-kind clinical trial. We hope to help the heart regenerate its own tissue and imp...